HER3 Is an Actionable Target in Advanced Prostate Cancer
Open Access
- 9 November 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 81 (24), 6207-6218
- https://doi.org/10.1158/0008-5472.can-21-3360
Abstract
HER3 is an actionable target in prostate cancer, especially with anti-HER3 immunoconjugates, and targeting HER3 warrants clinical evaluation in prospective trials.Other Versions
Funding Information
- Prostate Cancer UK (CEO13-3-002)
- U.S. Department of Defense
- Prostate Cancer Foundation (20131017, 20131017-1)
- Stand Up To Cancer (SU2C-AACR-DT0712)
- Cancer Research UK (CRM108X-A25144)
- Imperial Experimental Cancer Medicine Centre (ECMC-CRM064X)
- Daiichi Sankyo Company
- U.S. Department of Defense (W81XWH19-1-0337)
- Prostate Cancer UK (TLD-PF19-005)
- Medical Research Council
- Wellcome Trust Centre for Mitochondrial Research
- Chordoma Foundation
- Mark Foundation For Cancer Research
- Academy of Medical Sciences
- National Cancer Institute (R35 CA197745)
- National Institutes of Health (R01 CA251527)
This publication has 89 references indexed in Scilit:
- BLUEPRINT: mapping human blood cell epigenomesHaematologica, 2013
- Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and CufflinksNature Protocols, 2012
- Abiraterone and Increased Survival in Metastatic Prostate CancerThe New England Journal of Medicine, 2011
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate CancerCancer Cell, 2011
- Nrdp1-Mediated Regulation of ErbB3 Expression by the Androgen Receptor in Androgen-Dependent but not Castrate-Resistant Prostate Cancer CellsCancer Research, 2010
- Guidelines for the welfare and use of animals in cancer researchBritish Journal of Cancer, 2010
- ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylationProceedings of the National Academy of Sciences of the United States of America, 2010
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941Cancer Cell, 2009
- Targeting HER proteins in cancer therapy and the role of the non-target HER3British Journal of Cancer, 2007
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987